19 July 2012
Coumadin-induced skin necrosis in a 64 year-old female despite LMWH bridging therapy
Mehandar Kumar, Vanessa Mae Abrina, Sasikala ChittimireddyDOI: 10.12659/AJCR.883247
Am J Case Rep 2012; 13:157-159
Abstract
Background: Coumadin is the standard oral anticoagulant used in a variety of clinical conditions. Coumadin inhibits the vitamin-K dependent gamma-carboxylation of coagulation factors II, VII, IX, X and the anticoagulant proteins C and S. Rarely, skin necrosis occurs when the resultant initial procoagulant state in the first few days of starting coumadin leads to thrombosis and formation of blood clots tin the dermal capillaries. This in turn causes skin necrosis due to interruption in blood supply to the skin.
Case Report: We are presenting the case of a 64 year-old female admitted for acute respiratory distress secondary to newly-diagnosed pulmonary embolism. The patient was started on therapeutic doses of low molecular weight heparin (LMWH) and coumadin. After 5 days of treatment, the patient started complaining of pain and numbness in both upper extremities. Overnight, this rapidly progressed to manifest hemorrhagic bullae with necrotic areas. This was immediately recognized as coumadin-induced skin necrosis. Coumadin was stopped immediately. Vitamin K was administered and local wound care was provided. Therapeutic LMWH was continued. The skin lesions began to show improvement after 3 days.
Conclusions: In coumadin-induced skin necrosis, the patient initially presents with pain and erythema, followed by petechial lesions which progress to become purpuric. Hemorrhagic bullae with necrosis and eschar formation may soon develop. Once it is suspected, coumadin should be stopped and the patient should be given Vitamin K and FFP to reverse the effects of coumadin.
Keywords: Coumadin, Skin necrosis, low molecular weight heparin, Pulmonary Embolism
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946074
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946165
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946414
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.944665
Most Viewed Current Articles
21 Jun 2024 : Case report
89,141
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,239
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,805
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,697
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030